Skip to main content
Erschienen in: Urologie in der Praxis 3/2020

03.07.2020 | Urologie | Originalien

Stellenwert der Phytotherapeutika in der Therapie von Miktionsbeschwerden

verfasst von: PD Dr. med. Malte Rieken, Facharzt für Urologie, FEBU, Alexander Müller, Hans-Peter Schmid, Thomas Bschleipfer, Stephen Wyler, Hubert John

Erschienen in: Urologie in der Praxis | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die medikamentöse Therapie hat einen grossen Stellenwert in der Behandlung von Patienten mit Symptomen des unteren Harntrakts („lower urinary tract symptoms“, LUTS) bei Prostatavergrösserung. Neben synthetischen Präparaten stehen zahlreiche Phytotherapeutika zur Verfügung. Die Datenlage zu Phytotherapeutika in der Therapie von LUTS zeigt eine grosse Varianz und ist teils sogar widersprüchlich. Grundsätzlich muss jedes Präparat isoliert betrachtet werden, da sich Extraktionsverfahren und Zusammensetzung unterscheiden. Einzelne Präparate wie der hexanische Extrakt der Sägepalmfrucht (HESr) und das Kombinationspräparat aus Sägepalmfruchtextrakt und Brennnesselwurzelextrakt (PRO 160/120) konnten im Vergleich zu Plazebo eine signifikante Verbesserung sowie eine vergleichbare Wirkung wie synthetisch-medikamentöse Standardtherapien auf LUTS erzielen. Phytotherapeutika zeichnen sich durch eine gute Verträglichkeit, geringe Nebenwirkungen und eine unbeeinflusste Sexualfunktion aus. Phytotherapeutika, welche über suffiziente Daten aus randomisierten Studien verfügen, kommen für Patienten mit geringer bis moderater Symptomatik in Betracht, insbesondere wenn synthetische Präparate abgelehnt werden oder aufgrund ihres Nebenwirkungsspektrums für den Patienten nicht tolerabel sind.
Literatur
1.
Zurück zum Zitat Buck AC (2004) Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172:1792–1799CrossRef Buck AC (2004) Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172:1792–1799CrossRef
2.
Zurück zum Zitat Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, Koukoulis G et al (2019) The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol 37:539–544CrossRef Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, Koukoulis G et al (2019) The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol 37:539–544CrossRef
3.
Zurück zum Zitat Novara G, Giannarini G, Alcaraz A, Cozar-Olmo JM, Descazeaud A, Montorsi F et al (2016) Efficacy and safety of hexanic lipidosterolic extract of serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus 2:553–561CrossRef Novara G, Giannarini G, Alcaraz A, Cozar-Olmo JM, Descazeaud A, Montorsi F et al (2016) Efficacy and safety of hexanic lipidosterolic extract of serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus 2:553–561CrossRef
4.
Zurück zum Zitat Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, Minana Lopez B, Fernandez-Gomez JM, Angulo JC et al (2018) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R)) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int 122:1049–1065CrossRef Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, Minana Lopez B, Fernandez-Gomez JM, Angulo JC et al (2018) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R)) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int 122:1049–1065CrossRef
5.
Zurück zum Zitat Russo GI, Scandura C, Di Mauro M, Cacciamani G, Albersen M, Hatzichristodoulou G et al (2020) Clinical efficacy of serenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials. Eur Urol Focus. https://doi.org/10.1016/j.euf.2020.01.002CrossRefPubMed Russo GI, Scandura C, Di Mauro M, Cacciamani G, Albersen M, Hatzichristodoulou G et al (2020) Clinical efficacy of serenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials. Eur Urol Focus. https://​doi.​org/​10.​1016/​j.​euf.​2020.​01.​002CrossRefPubMed
6.
Zurück zum Zitat Dreikorn K (2000) Phytotherapeutic agents in the treatment of benign prostatic hyperplasia. Curr Urol Rep 1:103–109CrossRef Dreikorn K (2000) Phytotherapeutic agents in the treatment of benign prostatic hyperplasia. Curr Urol Rep 1:103–109CrossRef
7.
Zurück zum Zitat Nahata A, Dixit VK (2012) Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia 44(Suppl 1):396–409CrossRef Nahata A, Dixit VK (2012) Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia 44(Suppl 1):396–409CrossRef
8.
Zurück zum Zitat Schneider T, Rubben H (2004) Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months. Urologe A 43:302–306CrossRef Schneider T, Rubben H (2004) Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months. Urologe A 43:302–306CrossRef
9.
Zurück zum Zitat Safarinejad MR (2005) Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5:1–11CrossRef Safarinejad MR (2005) Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5:1–11CrossRef
10.
Zurück zum Zitat Gossell-Williams M, Davis A, O’Connor N (2006) Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food 9:284–286CrossRef Gossell-Williams M, Davis A, O’Connor N (2006) Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food 9:284–286CrossRef
11.
Zurück zum Zitat Wehrberger C, Dreikorn K, Schmitz-Drager BJ, Oelke M, Madersbacher S (2012) Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo. Urologe A 51:1674–1682CrossRef Wehrberger C, Dreikorn K, Schmitz-Drager BJ, Oelke M, Madersbacher S (2012) Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo. Urologe A 51:1674–1682CrossRef
12.
Zurück zum Zitat Friederich M, Theurer C, Schiebel-Schlosser G (2000) Prosta Fink Forte capsules in the treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245 patients. Forsch Komplementarmed Klass Naturheilkd 7:200–204PubMed Friederich M, Theurer C, Schiebel-Schlosser G (2000) Prosta Fink Forte capsules in the treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245 patients. Forsch Komplementarmed Klass Naturheilkd 7:200–204PubMed
13.
Zurück zum Zitat Allkanjari O, Vitalone A (2015) What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 126:42–56CrossRef Allkanjari O, Vitalone A (2015) What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 126:42–56CrossRef
14.
Zurück zum Zitat Berges RR, Windeler J, Trampisch HJ, Senge T (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529–1532CrossRef Berges RR, Windeler J, Trampisch HJ, Senge T (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529–1532CrossRef
15.
Zurück zum Zitat Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80:427–432CrossRef Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80:427–432CrossRef
16.
Zurück zum Zitat Pigat N, Reyes-Gomez E, Boutillon F, Palea S, Barry Delongchamps N, Koch E et al (2019) Combined sabal and urtica extracts (WS((R)) 1541) exert anti-proliferative and anti-inflammatory effects in a mouse model of benign prostate hyperplasia. Front Pharmacol 10:311CrossRef Pigat N, Reyes-Gomez E, Boutillon F, Palea S, Barry Delongchamps N, Koch E et al (2019) Combined sabal and urtica extracts (WS((R)) 1541) exert anti-proliferative and anti-inflammatory effects in a mouse model of benign prostate hyperplasia. Front Pharmacol 10:311CrossRef
17.
Zurück zum Zitat Lopatkin N, Sivkov A, Schlafke S, Funk P, Medvedev A, Engelmann U (2007) Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int Urol Nephrol 39:1137–1146CrossRef Lopatkin N, Sivkov A, Schlafke S, Funk P, Medvedev A, Engelmann U (2007) Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int Urol Nephrol 39:1137–1146CrossRef
18.
Zurück zum Zitat Engelmann U, Walther C, Bondarenko B, Funk P, Schlafke S (2006) Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung 56:222–229PubMed Engelmann U, Walther C, Bondarenko B, Funk P, Schlafke S (2006) Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung 56:222–229PubMed
19.
Zurück zum Zitat Sokeland J, Albrecht J (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe A 36:327–333CrossRef Sokeland J, Albrecht J (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe A 36:327–333CrossRef
20.
Zurück zum Zitat Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P (1996) Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29:155–167PubMed Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P (1996) Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29:155–167PubMed
21.
Zurück zum Zitat Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A et al (2017) The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol 6:295–304CrossRef Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A et al (2017) The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol 6:295–304CrossRef
22.
Zurück zum Zitat Herberts M, Butcher M, Kohler T (2016) The effect of LUTS/BPH and treatments on ejaculatory function. Curr Urol Rep 17:48CrossRef Herberts M, Butcher M, Kohler T (2016) The effect of LUTS/BPH and treatments on ejaculatory function. Curr Urol Rep 17:48CrossRef
23.
Zurück zum Zitat Kapoor A (2012) Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol 19(Suppl 1):10–17PubMed Kapoor A (2012) Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol 19(Suppl 1):10–17PubMed
24.
Zurück zum Zitat Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T et al (2010) Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med 7:3115–3126CrossRef Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T et al (2010) Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med 7:3115–3126CrossRef
25.
Zurück zum Zitat van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66:287–301CrossRef van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66:287–301CrossRef
26.
Zurück zum Zitat Ye Z, Huang J, Zhou L, Chen S, Wang Z, Ma L et al (2019) Efficacy and safety of serenoa repens extract among patients with benign prostatic hyperplasia in China: a multicenter, randomized, double-blind, placebo-controlled trial. Urology 129:172–179CrossRef Ye Z, Huang J, Zhou L, Chen S, Wang Z, Ma L et al (2019) Efficacy and safety of serenoa repens extract among patients with benign prostatic hyperplasia in China: a multicenter, randomized, double-blind, placebo-controlled trial. Urology 129:172–179CrossRef
27.
Zurück zum Zitat Zlotta AR, Teillac P, Raynaud JP, Schulman CC (2005) Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 48:269–276CrossRef Zlotta AR, Teillac P, Raynaud JP, Schulman CC (2005) Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 48:269–276CrossRef
28.
Zurück zum Zitat Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC et al (2018) A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 121:647–658CrossRef Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC et al (2018) A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 121:647–658CrossRef
Metadaten
Titel
Stellenwert der Phytotherapeutika in der Therapie von Miktionsbeschwerden
verfasst von
PD Dr. med. Malte Rieken, Facharzt für Urologie, FEBU
Alexander Müller
Hans-Peter Schmid
Thomas Bschleipfer
Stephen Wyler
Hubert John
Publikationsdatum
03.07.2020
Verlag
Springer Vienna
Schlagwort
Urologie
Erschienen in
Urologie in der Praxis / Ausgabe 3/2020
Print ISSN: 2661-8737
Elektronische ISSN: 2661-8745
DOI
https://doi.org/10.1007/s41973-020-00101-2

Weitere Artikel der Ausgabe 3/2020

Urologie in der Praxis 3/2020 Zur Ausgabe

Die Urologische Blickdiagnose

Blickdiagnose Urologie